AXIM (AXIM Biotechnologies) Debt-to-Equity: -0.72 (As of Jun. 2025)


What is AXIM Biotechnologies Debt-to-Equity?

AXIM Biotechnologies AXIM Debt-to-Equity is -0.72 as of Jun. 2025. Among 963 Biotechnology companies, AXIM Biotechnologies ranks worse than 103842.06% on this metric.

AXIM Biotechnologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2025 was $0.10 Mil. AXIM Biotechnologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2025 was $7.44 Mil. AXIM Biotechnologies's Total Stockholders Equity for the quarter that ended in Jun. 2025 was $-10.43 Mil. AXIM Biotechnologies's debt to equity for the quarter that ended in Jun. 2025 was -0.72.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for AXIM Biotechnologies's Debt-to-Equity or its related term are showing as below:

AXIM's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.16
* Ranked among companies with meaningful Debt-to-Equity only.

AXIM Biotechnologies  (OTCPK:AXIM) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

AXIM Biotechnologies Debt-to-Equity Related Terms

AXIM Biotechnologies Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for AXIM Biotechnologies's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AXIM Biotechnologies Debt-to-Equity Chart

AXIM Biotechnologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.03 -2.87 -1.17 -0.77 -0.69

AXIM Biotechnologies Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.90 -0.71 -0.69 -0.69 -0.72

AXIM vs ZVSA, HEPA, ISCO: Debt-to-Equity Comparison

For the Biotechnology subindustry, AXIM Biotechnologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AXIM Biotechnologies Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AXIM Biotechnologies's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where AXIM Biotechnologies's Debt-to-Equity falls into.


AXIM Biotechnologies Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

AXIM Biotechnologies's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.077 + 7.104) / -10.42
=-0.69

AXIM Biotechnologies's Debt to Equity Ratio for the quarter that ended in Jun. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.102 + 7.444) / -10.426
=-0.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -0.72 mean?
AXIM Biotechnologies (AXIM) has a Debt-to-Equity of -0.72 as of Jun. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on AXIM Biotechnologies and its competitors. According to the industry distribution chart, AXIM Biotechnologies ranks #999999 out of 963 companies in the Biotechnology industry.
Is AXIM Biotechnologies' Debt-to-Equity too high?
AXIM Biotechnologies' current Debt-to-Equity is -0.72. Based on the distribution chart, AXIM Biotechnologies ranks #999999 out of 963 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does AXIM Biotechnologies' Debt-to-Equity compare to ZVSA and HEPA?
According to the Biotechnology industry distribution chart, AXIM Biotechnologies ranks #999999 out of 963 companies for Debt-to-Equity. This places AXIM Biotechnologies in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on AXIM Biotechnologies and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AXIM Biotechnologies's current Debt-to-Equity is -0.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AXIM Biotechnologies stock overvalued right now?
AXIM Biotechnologies (AXIM) has a current Debt-to-Equity of -0.72. The current Debt-to-Equity is -0.72. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For AXIM Biotechnologies (AXIM), the current Debt-to-Equity is -0.72 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AXIM Biotechnologies Business Description

Address 6048 Cornerstone Court West, Suite E1, San Diego, CA, USA, 92121
AXIM Biotechnologies Inc is a integrated research and development company and developer of diagnostic healthcare solutions serving to enhance the health of people. The company focuses on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, The company owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells.